OncoMatch/Clinical Trials/NCT06627751
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Is NCT06627751 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Mezigdomide and Carfilzomib for extramedullary disease in multiple myeloma.
Treatment: Mezigdomide · Carfilzomib · Dexamethasone — This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease \[EMD\]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a type of corticosteroid and is used to kill myeloma cells. It is used with other drugs to treat multiple myeloma. Giving MeziKD may kill more cancer cells in patients with relapsed/refractory multiple myeloma (RRMM) with EMD.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: peripheral stem cell transplant
Exception: within 12 weeks of study enrollment
Prior peripheral stem cell transplant within 12 weeks of study enrollment
Cannot have received: radiation therapy
Exception: within 14 days prior to cycle 1 day 1; exception if radiation portal covered ≤ 5% of the bone marrow reserve
Radiotherapy within 14 days prior to cycle 1 day 1. However, if the radiation portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy
Cannot have received: mezigdomide (mezigdomide)
Prior treatment with mezigdomide
Cannot have received: carfilzomib (carfilzomib)
Exception: carfilzomib-refractory in the most recent line of therapy
Carfilzomib-refractory in the most recent line of therapy
Cannot have received: other ongoing anti-myeloma therapy
Exception: bisphosphonates and low dose corticosteroids for symptom management and comorbid conditions allowed; corticosteroid dose should be stable for at least 7 days prior to registration
Other ongoing anti-myeloma therapy. Patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids for symptom management and comorbid conditions. Doses of corticosteroid should be stable for at least 7 days prior to patient registration
Lab requirements
Blood counts
Absolute neutrophil count: ≥ 1 x 10^9/L; Platelets: ≥ 75 x 10^9/L
Kidney function
Estimated creatinine clearance ≥ 30 mL/min (Cockroft-Gault)
Liver function
Total bilirubin: ≤ 1.5 x upper limit of normal (ULN); AST/ALT: ≤ 3 x ULN
Cardiac function
Adequate cardiac pump function with a left ventricular ejection fraction of ≥ 40%
Absolute neutrophil count: ≥ 1 x 10^9/L; Platelets: ≥ 75 x 10^9/L; Total bilirubin: ≤ 1.5 x ULN; AST/ALT: ≤ 3 x ULN; Estimated creatinine clearance ≥ 30 mL/min (Cockroft-Gault); Adequate cardiac pump function with a left ventricular ejection fraction of ≥ 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Roswell Park Cancer Institute · Buffalo, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify